Promoter Methylation of IGFBP-3 and P53 Expression in Ovarian Endometrioid Carcinoma

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2009 Dec 17

PMID 20003326

Citations 25

Authors

Pao-Ling Torng

Ching-Wei Lin

Michael Wy Chan

Hui-Wen Yang

Su-Cheng Huang

Chin-Tarng Lin

Affiliations

Soon will be listed here.

Abstract

Background: Insulin-like growth factor binding protein (IGFBP-3) is an antiproliferative, pro-apoptotic and invasion suppressor protein which is transcriptionally regulated by p53. Promoter methylation has been linked to gene silencing and cancer progression. We studied the correlation between IGFBP-3 and p53 expression as well as IGFBP-3 promoter methylation in ovarian endometrioid carcinoma (OEC) by immunohistochemical staining and quantitative methylation-specific PCR (qMSP). Additionally, we assessed the molecular regulatory mechanism of wild type (wt) p53 on IGFBP-3 expression using two subclones of OEC, the OVTW59-P0 (low invasive) and P4 (high invasive) sublines.

Results: In 60 cases of OEC, 40.0% showed lower IGFBP-3 expression which was significantly correlated with higher IGFBP-3 promoter methylation. p53 overexpression was detected in 35.0% of OEC and was unrelated to clinical outcomes and IGFBP-3. By Kaplan-Meier analysis, patients with lower IGFBP-3, higher IGFBP-3 promoter methylation, and normal p53 were associated most significantly with lower survival rates. In OEC cell line, IGFBP-3 expression was correlated with IGFBP-3 promoter methylation. IGFBP-3 expression was restored after treatment with a DNA methy-transferase inhibitors (5-aza-deoxycytidine) and suppressed by a p53 inhibitor (pifithrin-alpha). The putative p53 regulatory sites on the promoter of IGFBP-3 were identified at -210, -206, -183 and -179 bases upstream of the transcription start site. Directed mutagenesis at these sites quantitatively reduced the transcription activity of IGFBP-3.

Conclusion: Our data suggests that IGFBP-3 silencing through IGFBP-3 promoter methylation in the absence of p53 overexpression is associated with cancer progression. These results support a potential role of IGFBP-3 methylation in the carcinogenesis of OEC.

Citing Articles

Current data and future perspectives on DNA methylation in ovarian cancer (Review).

Fu M, Deng F, Chen J, Fu L, Lei J, Xu T Int J Oncol. 2024; 64(6).

PMID: 38757340 PMC: 11095605. DOI: 10.3892/ijo.2024.5650.

Cellular and clinical impact of protein phosphatase enzyme epigenetic silencing in multiple cancer tissues.

Wiltshire E, de Moura M, Pineyro D, Joshi R Hum Genomics. 2024; 18(1):24.

PMID: 38475971 PMC: 10935810. DOI: 10.1186/s40246-024-00592-x.

Molecular mechanism of the anti-gastric cancer activity of 1,2,3,6-tetra-O-galloyl-β-D-glucose isolated from Trapa bispinosa Roxb. shell in vitro.

Wang L, Yin D, Fan Y, Min T, Yi Y, Wang H PLoS One. 2022; 17(6):e0269013.

PMID: 35653387 PMC: 9162355. DOI: 10.1371/journal.pone.0269013.

Differential expression of hypoxia-inducible factors related to the invasiveness of epithelial ovarian cancer.

Shih H, Chang H, Chen C, Torng P Sci Rep. 2021; 11(1):22925.

PMID: 34824343 PMC: 8616920. DOI: 10.1038/s41598-021-02400-1.

IGFBP-3 and TGF-β inhibit growth in epithelial cells by stimulating type V TGF-β receptor (TβR-V)-mediated tumor suppressor signaling.

Chen C, Huang F, Huang S, Huang J FASEB Bioadv. 2021; 3(9):709-729.

PMID: 34485840 PMC: 8409558. DOI: 10.1096/fba.2021-00016.

References

Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B . Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J Biol Chem. 2006; 281(34):24588-601. DOI: 10.1074/jbc.M509463200. View

Costello J, Fruhwald M, Smiraglia D, Rush L, Robertson G, Gao X . Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24(2):132-8. DOI: 10.1038/72785. View

Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T . Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002; 176(2):149-58. DOI: 10.1016/s0304-3835(01)00736-4. View

Watts G, Futscher B, Holtan N, DeGeest K, Domann F, Rose S . DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics. 2008; 1:47. PMC: 2566571. DOI: 10.1186/1755-8794-1-47. View

Hanafusa T, Shinji T, Shiraha H, Nouso K, Iwasaki Y, Yumoto E . Functional promoter upstream p53 regulatory sequence of IGFBP3 that is silenced by tumor specific methylation. BMC Cancer. 2005; 5:9. PMC: 548269. DOI: 10.1186/1471-2407-5-9. View

Firth S, Baxter R . Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23(6):824-54. DOI: 10.1210/er.2001-0033. View

Grimberg A, Coleman C, Burns T, Himelstein B, Koch C, Cohen P . p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab. 2005; 90(6):3568-74. PMC: 4145590. DOI: 10.1210/jc.2004-1213. View

Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A . Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol. 2008; 62(9):777-85. DOI: 10.1136/jcp.2008.056101. View

Wiley A, Katsaros D, Fracchioli S, Yu H . Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer. 2006; 16(1):210-8. DOI: 10.1111/j.1525-1438.2006.00299.x. View

10.

Chang Y, Wang L, Suh Y, Mao L, Karpen S, Khuri F . Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene. 2004; 23(39):6569-80. DOI: 10.1038/sj.onc.1207882. View

11.

Chang Y, Wang L, Liu D, Mao L, Hong W, Khuri F . Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res. 2002; 8(12):3669-75. View

12.

Bell D . Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005; 18 Suppl 2:S19-32. DOI: 10.1038/modpathol.3800306. View

13.

Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner G, Fuchs C . IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Neoplasia. 2007; 9(12):1091-8. PMC: 2134905. DOI: 10.1593/neo.07760. View

14.

Mulero-Navarro S, Esteller M . Epigenetic biomarkers for human cancer: the time is now. Crit Rev Oncol Hematol. 2008; 68(1):1-11. DOI: 10.1016/j.critrevonc.2008.03.001. View

15.

Ohwada M, Suzuki M, Suzuki T, Hiratsuka M, Kawai T, Saito K . Problems with peritoneal cytology in second-look laparotomy performed in patients with epithelial ovarian carcinoma. Cancer. 2001; 93(6):376-80. DOI: 10.1002/cncr.10137. View

16.

Darcy K, Brady W, McBroom J, Bell J, Young R, McGuire W . Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study. Gynecol Oncol. 2008; 111(3):487-95. PMC: 2615492. DOI: 10.1016/j.ygyno.2008.08.020. View

17.

Bourdon J, LELONG J, Dessen P, May P, Debuire B, May E . Further characterisation of the p53 responsive element--identification of new candidate genes for trans-activation by p53. Oncogene. 1997; 14(1):85-94. DOI: 10.1038/sj.onc.1200804. View

18.

Hogdall E, Christensen L, Hogdall C, Frederiksen K, Gayther S, Blaakaer J . Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS. 2008; 116(5):400-9. DOI: 10.1111/j.1600-0463.2008.00917.x. View

19.

McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K . Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 1996; 23(5 Suppl 12):40-7. View

20.

Chan M, Wei S, Wen P, Wang Z, Matei D, Liu J . Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res. 2005; 11(20):7376-83. DOI: 10.1158/1078-0432.CCR-05-1100. View